Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have earned a consensus rating of “Moderate Buy” from the twelve brokerages that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $33.5909.

A number of brokerages have recently issued reports on ROIV. TD Cowen upped their price target on Roivant Sciences from $38.00 to $41.00 and gave the stock a “buy” rating in a research report on Thursday, May 21st. Guggenheim boosted their target price on Roivant Sciences from $30.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, May 26th. Weiss Ratings cut Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Leerink Partners set a $42.00 price target on Roivant Sciences in a report on Thursday, May 21st. Finally, Piper Sandler restated an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, May 21st.

Insider Activity at Roivant Sciences

In related news, CAO Jennifer Humes sold 13,538 shares of the company’s stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $28.37, for a total value of $384,073.06. Following the sale, the chief accounting officer owned 84,191 shares in the company, valued at $2,388,498.67. This represents a 13.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Eric Venker sold 200,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $33.16, for a total value of $6,632,000.00. Following the completion of the sale, the chief executive officer owned 1,613,063 shares in the company, valued at approximately $53,489,169.08. This represents a 11.03% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 903,312 shares of company stock worth $27,437,883 over the last quarter. Insiders own 10.80% of the company’s stock.

Institutional Investors Weigh In On Roivant Sciences

Hedge funds have recently bought and sold shares of the stock. SBI Securities Co. Ltd. boosted its position in Roivant Sciences by 1,740.3% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock worth $27,000 after purchasing an additional 1,166 shares in the last quarter. Allworth Financial LP boosted its position in Roivant Sciences by 48.1% in the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after purchasing an additional 583 shares in the last quarter. Parallel Advisors LLC boosted its position in Roivant Sciences by 33.7% in the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock worth $57,000 after purchasing an additional 520 shares in the last quarter. Kestra Advisory Services LLC purchased a new stake in Roivant Sciences in the 4th quarter worth approximately $47,000. Finally, Bessemer Group Inc. boosted its position in Roivant Sciences by 21.8% in the 1st quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock worth $69,000 after purchasing an additional 441 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Stock Performance

NASDAQ:ROIV opened at $34.07 on Monday. The firm has a 50-day simple moving average of $29.66 and a 200-day simple moving average of $26.81. Roivant Sciences has a one year low of $10.70 and a one year high of $34.68. The firm has a market cap of $24.51 billion, a P/E ratio of -56.78 and a beta of 1.13.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings data on Wednesday, May 20th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of ($0.29) by $0.57. Roivant Sciences had a negative net margin of 3,629.19% and a negative return on equity of 20.54%. The firm had revenue of $2.52 million during the quarter, compared to analyst estimates of $3.41 million. During the same quarter in the previous year, the business posted ($0.29) EPS. On average, research analysts predict that Roivant Sciences will post -1.83 EPS for the current fiscal year.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.